ode15s (MathWorks Inc)
MathWorks Inc is a verified supplier 
97
Structured Review
MathWorks Inc
ode15s
“ode15s” solver of MATLAB, while the stochastic simulations were performed using the “adaptivesa” solver of COPASI in every case. " width="250" height="auto" />
Ode15s, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 97/100, based on 606 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ode+integration+algorithm+ode15s/SimBiology/pmc12583811-545-6-5
Average 97 stars, based on 606 article reviews
“ode15s” solver of MATLAB, while the stochastic simulations were performed using the “adaptivesa” solver of COPASI in every case. " width="250" height="auto" />Ode15s, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 97/100, based on 606 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ode+integration+algorithm+ode15s/SimBiology/pmc12583811-545-6-5
Average 97 stars, based on 606 article reviews
ode15s - by Bioz Stars,
2026-10
97/100 stars
Images
1) Product Images from "A tool for modeling gene regulatory networks (GRN_modeler) and its applications to synthetic biology"
Article Title: A tool for modeling gene regulatory networks (GRN_modeler) and its applications to synthetic biology
Journal: Molecular Systems Biology
doi: 10.1038/s44320-025-00148-8
Figure Legend Snippet: I) The repressilator ( A ) Topology of the repressilator. ( B ) Topology of the circuit in the interface generated by the make_graph() method: the red dots N 1 , N 2 , and N 3 represent the nodes in the circuit. The red arrows denote the directed edges of the graph, illustrating the repression interactions between nodes. Additionally, the yellow dots N 1 ∣ − N 3 , N 2 ∣ − N 1 , and N 3 ∣ − N 2 represent the regulatory interactions. For example, N 1 ∣ − N 3 denotes that node N 1 is repressed by N 3 . ( C ) Deterministic and ( D ) stochastic simulations of the repressilator using the Elowitz model, as described in Appendix Table in the . The detailed information about the model is available in the file “repressilator.html". II) Redesigned repressilator for an independent modulation of amplitude and frequency. ( A ) Topology of the redesigned repressilator. “C" and “L" are proteases, “I 1 " and “I 2 " external inducers, “U" and “Y" transcription factors activating N 4 and N 2 , respectively. The dotted gray lines indicate which proteins are degraded by the proteases. ( B ) Topology of the circuit in the interface. ( C ) The effect of the inducers on the amplitude of N 4 . ( D ) The effect of the inducers on the time period of N 4 . The detailed information about the model is available in the file “Tomazou.html". III) The CRISPRlator circuit. ( A ) Topology of the CRISPRlator. ( B ) Topology of the circuit in the interface. For example, N 1 NOHILL∣-N 3 denotes that node N 1 is repressed by N 3 through an input named NOHILL, which corresponds to the CRISPRi interaction in the node model. This repression is incorporated into the system by introducing new reactions (R 6 and R 7 in Appendix Table ), where the dCas:sgRNA N3 complex binds to DNA N1 , inhibiting transcription at node N 1 . ( C ) Deterministic and ( D ) stochastic simulations of the CRISPRlator generated by the model detailed in Appendix Table in the . The detailed information about the model is available in the file “CRISPR.html”. The deterministic simulations were fulfilled with the “ode15s” solver of MATLAB, while the stochastic simulations were performed using the “adaptivesa” solver of COPASI in every case.
Techniques Used: Generated, CRISPR
Related Articles
Software:Article Title: Consensus Computational Immunogenicity Modelling of Botulinum Neurotoxin Serotypes: Cross-Platform Validation, Uncertainty Quantification, and Relative Risk Assessment. Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Article Title: A multiscale quantitative systems pharmacology platform for early screening of MMAE-based antibody-drug conjugates. Article Snippet: .. Model development and simulations were performed using Activation Assay:Article Title: Consensus Computational Immunogenicity Modelling of Botulinum Neurotoxin Serotypes: Cross-Platform Validation, Uncertainty Quantification, and Relative Risk Assessment. Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Clinical Proteomics:Article Title: Consensus Computational Immunogenicity Modelling of Botulinum Neurotoxin Serotypes: Cross-Platform Validation, Uncertainty Quantification, and Relative Risk Assessment. Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Immunopeptidomics:Article Title: Consensus Computational Immunogenicity Modelling of Botulinum Neurotoxin Serotypes: Cross-Platform Validation, Uncertainty Quantification, and Relative Risk Assessment. Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Infection:Article Title: Evolutionary digital twin framework for optimal aminoglycoside dosing in neonates with suspected sepsis. Article Snippet: .. The mechanistic ODEs specifying the PBPK–PD model were developed using the Control:Article Title: Evolutionary digital twin framework for optimal aminoglycoside dosing in neonates with suspected sepsis. Article Snippet: .. The mechanistic ODEs specifying the PBPK–PD model were developed using the other:Article Title: Inhalation exposure and uptake modeling of particle-associated phthalate: from respiratory deposition and clearance to organ toxicokinetics. Article Snippet: This study aimed to develop a novel hybrid computational fluid-particle dynamics (CFPD)–physiologically-based pharmacokinetics (PBPK) model to elucidate the toxicokinetics of particle-associated di(2-Ethylhexyl) phthalate (DEHP) in the human body via inhalation exposure.. Initially, a steady mucus flow was simulated with constant rates for the upper and lower respiratory tracts.. The desorption, dynamics, and tissue absorption of DEHP were simultaneously described by the Eulerian approach and the mucus–tissue–blood model. Mucociliary clearance effects were examined against the DEHP and its particle carriers using the steady rate constant. Drug discovery:Article Title: Evolutionary digital twin framework for optimal aminoglycoside dosing in neonates with suspected sepsis. Article Snippet: .. Recapitulation of observed amikacin pharmacokinetics The fully calibrated PBPK–PD model was implemented in Platinum:Article Title: Integrating a Tumor Size-Overall Survival Model Into a Spatial Quantitative Systems Pharmacology Framework for Antibody-Drug Conjugates in Non-Small Cell Lung Cancer. Article Snippet: .. The model was implemented in |